Health Economics›Ovarian cancer›Second-line therapy for relapsed or recurrent disease platinum-sensitive

Second-line therapy for relapsed or recurrent disease platinum-sensitive

Ovarian cancer · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 10 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin, Pegylated liposomal doxorubicin, Bevacizumab Variant #01	—	R 78 013	28d	11.8 mo	—	13	R 1 014 170 PFS proxy	3
Carboplatin and Paclitaxel (CP) and Olaparib Variant #01	—	R 75 359	21d	12.2 mo	—	18	R 1 356 466 PFS proxy	1
nab-Paclitaxel monotherapy Variant #01	—	R 45 710	28d	~5.5 mo	~11.5 mo	~6	~R 274 259 PFS proxy · indirect	2
Carboplatin and Paclitaxel (CP) and Bevacizumab Variant #12	—	R 45 174	21d	11.6 mo	42.2 mo	17	R 767 962 PFS proxy	3
Carboplatin and Gemcitabine (GCb) and Bevacizumab Variant #01	—	R 32 286	21d	11.7 mo	33.6 mo	17	R 548 866 PFS proxy	5
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	—	~10.3 mo	—	—	1
Carboplatin and Pegylated liposomal doxorubicin Variant #01	—	R 14 626	28d	10.1 mo	21.4 mo	11	R 160 882 PFS proxy	4
Carboplatin and Paclitaxel (CP) Variant #38	—	R 5 031	21d	9.6 mo	29.0 mo	14	R 70 430 PFS proxy	8
Carboplatin and Gemcitabine (GCb) Variant #01	—	R 3 663	21d	8.7 mo	32.9 mo	13	R 47 620 PFS proxy	5
Carboplatin and Docetaxel (DCb) Variant #01	—	R 3 300	21d	~4.7 mo	~22.3 mo	~7	~R 23 101 PFS proxy · indirect	4
Etoposide monotherapy Variant #01	—	R 2 872	28d	—	—	—	—	—
Carboplatin monotherapy Variant #01	—	R 1 231	21d	5.8 mo	21.0 mo	9	R 11 076 PFS proxy	2
Cisplatin and Paclitaxel (TP) Variant #01	—	R 716	10d	—	29.0 mo	—	—	1
Rucaparib monotherapy Variant #01 Partial	—	—	28d	~20.2 mo	~27.7 mo	~22	—	7

14 of 14 regimens shown